These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 11502532)

  • 1. New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins.
    Jiang S; Prigge ST; Wei L; Gao Ye ; Hudson TH; Gerena L; Dame JB; Kyle DE
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2577-84. PubMed ID: 11502532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
    Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
    J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors.
    Moura PA; Dame JB; Fidock DA
    Antimicrob Agents Chemother; 2009 Dec; 53(12):4968-78. PubMed ID: 19752273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azole-based non-peptidomimetic plasmepsin inhibitors.
    Kinena L; Leitis G; Kanepe-Lapsa I; Bobrovs R; Jaudzems K; Ozola V; Suna E; Jirgensons A
    Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800151. PubMed ID: 30063266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum.
    Miura T; Hidaka K; Azai Y; Kashimoto K; Kawasaki Y; Chen SE; de Freitas RF; Freire E; Kiso Y
    Bioorg Med Chem Lett; 2014 Apr; 24(7):1698-701. PubMed ID: 24631188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant expression and enzymatic subsite characterization of plasmepsin 4 from the four Plasmodium species infecting man.
    Li T; Yowell CA; Beyer BB; Hung SH; Westling J; Lam MT; Dunn BM; Dame JB
    Mol Biochem Parasitol; 2004 May; 135(1):101-9. PubMed ID: 15287591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.
    Mohapatra SC; Tiwari HK; Singla M; Rathi B; Sharma A; Mahiya K; Kumar M; Sinha S; Chauhan SS
    J Biol Inorg Chem; 2010 Mar; 15(3):373-85. PubMed ID: 19946719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting Structural Dynamics To Design Open-Flap Inhibitors of Malarial Aspartic Proteases.
    Bobrovs R; Jaudzems K; Jirgensons A
    J Med Chem; 2019 Oct; 62(20):8931-8950. PubMed ID: 31062983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes.
    Nöteberg D; Hamelink E; Hultén J; Wahlgren M; Vrang L; Samuelsson B; Hallberg A
    J Med Chem; 2003 Feb; 46(5):734-46. PubMed ID: 12593654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent inhibitors of malarial aspartic proteases, the plasmepsins, by hydroformylation of substituted 7-azanorbornenes.
    Aureggi V; Ehmke V; Wieland J; Schweizer WB; Bernet B; Bur D; Meyer S; Rottmann M; Freymond C; Brun R; Breit B; Diederich F
    Chemistry; 2013 Jan; 19(1):155-64. PubMed ID: 23161835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations.
    Valiente PA; Batista PR; Pupo A; Pons T; Valencia A; Pascutti PG
    Proteins; 2008 Nov; 73(2):440-57. PubMed ID: 18442137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D.
    Zogota R; Kinena L; Withers-Martinez C; Blackman MJ; Bobrovs R; Pantelejevs T; Kanepe-Lapsa I; Ozola V; Jaudzems K; Suna E; Jirgensons A
    Eur J Med Chem; 2019 Feb; 163():344-352. PubMed ID: 30529637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmodium falciparum, P. vivax, and P. malariae: a comparison of the active site properties of plasmepsins cloned and expressed from three different species of the malaria parasite.
    Westling J; Yowell CA; Majer P; Erickson JW; Dame JB; Dunn BM
    Exp Parasitol; 1997 Nov; 87(3):185-93. PubMed ID: 9371083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
    Parikh S; Gut J; Istvan E; Goldberg DE; Havlir DV; Rosenthal PJ
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2983-5. PubMed ID: 15980379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target.
    Nezami A; Luque I; Kimura T; Kiso Y; Freire E
    Biochemistry; 2002 Feb; 41(7):2273-80. PubMed ID: 11841219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmepsin Inhibitors in Antimalarial Drug Discovery: Medicinal Chemistry and Target Validation (2000 to Present).
    Cheuka PM; Dziwornu G; Okombo J; Chibale K
    J Med Chem; 2020 May; 63(9):4445-4467. PubMed ID: 31913032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum.
    Qidwai T; Yadav DK; Khan F; Dhawan S; Bhakuni RS
    Curr Pharm Des; 2012; 18(37):6133-54. PubMed ID: 22670592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimalarials: Review of Plasmepsins as Drug Targets and HIV Protease Inhibitors Interactions.
    Miller Iii WA; Teye J; Achieng AO; Mogire RM; Akala H; Ong'echa JM; Rathi B; Durvasula R; Kempaiah P; Kwofie SK
    Curr Top Med Chem; 2019; 18(23):2022-2028. PubMed ID: 30499404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
    Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplasmodial activity of hydroxyethylamine analogs: Synthesis, biological activity and structure activity relationship of plasmepsin inhibitors.
    Kumar Singh A; Rajendran V; Singh S; Kumar P; Kumar Y; Singh A; Miller W; Potemkin V; Poonam ; Grishina M; Gupta N; Kempaiah P; Durvasula R; Singh BK; Dunn BM; Rathi B
    Bioorg Med Chem; 2018 Jul; 26(13):3837-3844. PubMed ID: 29983285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.